131 related articles for article (PubMed ID: 20002777)
1. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme.
Moore DM; Zhang W; Yip B; Genebat M; Lima VD; Montaner JS; Hogg RS
HIV Med; 2010 May; 11(5):299-307. PubMed ID: 20002777
[TBL] [Abstract][Full Text] [Related]
2. Physicians' patient base composition and mortality among people living with HIV who initiated antiretroviral therapy in a universal care setting.
Allan B; Closson K; Collins AB; Kibel M; Pan S; Cui Z; McLinden T; Parashar S; Lima VD; Chia J; Yip B; Barrios R; Montaner JSG; Hogg RS
BMJ Open; 2019 Mar; 9(3):e023957. PubMed ID: 30898806
[TBL] [Abstract][Full Text] [Related]
3. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
4. Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort.
Patterson S; Cescon A; Samji H; Cui Z; Yip B; Lepik KJ; Moore D; Lima VD; Nosyk B; Harrigan PR; Montaner JS; Shannon K; Wood E; Hogg RS
Int J Epidemiol; 2015 Feb; 44(1):58-67. PubMed ID: 24639444
[TBL] [Abstract][Full Text] [Related]
5. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Adedeji TA; Adebisi SA; Adedeji NO
Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
[TBL] [Abstract][Full Text] [Related]
6. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.
Samji H; Taha TE; Moore D; Burchell AN; Cescon A; Cooper C; Raboud JM; Klein MB; Loutfy MR; Machouf N; Tsoukas CM; Montaner JS; Hogg RS;
HIV Med; 2015 Feb; 16(2):76-87. PubMed ID: 25174373
[TBL] [Abstract][Full Text] [Related]
7. Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada.
Lourenço L; Samji H; Nohpal A; Chau W; Colley G; Lepik K; Barrios R; Lima V; Hogg RS; Montaner J; Kesselring S; Moore DM
HIV Med; 2015 Jul; 16(6):337-45. PubMed ID: 25721157
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
9. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
[TBL] [Abstract][Full Text] [Related]
10. Nonstructured treatment interruptions among injection drug users in Baltimore, MD.
Kavasery R; Galai N; Astemborski J; Lucas GM; Celentano DD; Kirk GD; Mehta SH
J Acquir Immune Defic Syndr; 2009 Apr; 50(4):360-6. PubMed ID: 19214124
[TBL] [Abstract][Full Text] [Related]
11. Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD.
Jiamsakul A; Kerr SJ; Ng OT; Lee MP; Chaiwarith R; Yunihastuti E; Van Nguyen K; Pham TT; Kiertiburanakul S; Ditangco R; Saphonn V; Sim BL; Merati TP; Wong W; Kantipong P; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Oka S; Mustafa M; Ratanasuwan W; Petersen B; Law M; Kumarasamy N;
Trop Med Int Health; 2016 May; 21(5):662-74. PubMed ID: 26950901
[TBL] [Abstract][Full Text] [Related]
12. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users.
Uhlmann S; Milloy MJ; Kerr T; Zhang R; Guillemi S; Marsh D; Hogg RS; Montaner JS; Wood E
Addiction; 2010 May; 105(5):907-13. PubMed ID: 20331553
[TBL] [Abstract][Full Text] [Related]
13. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.
Nosyk B; Zang X; Min JE; Krebs E; Lima VD; Milloy MJ; Shoveller J; Barrios R; Harrigan PR; Kerr T; Wood E; Montaner JSG
Lancet HIV; 2017 Jul; 4(7):e303-e310. PubMed ID: 28366707
[TBL] [Abstract][Full Text] [Related]
14. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
15. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection.
Childers ME; Woods SP; Letendre S; McCutchan JA; Rosario D; Grant I; Mindt MR; Ellis RJ;
J Neurovirol; 2008 Nov; 14(6):550-7. PubMed ID: 19016380
[TBL] [Abstract][Full Text] [Related]
16. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
[TBL] [Abstract][Full Text] [Related]
17. Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996-2015.
Wang L; Min JE; Zang X; Sereda P; Harrigan RP; Montaner JSG; Nosyk B
Clin Infect Dis; 2017 Oct; 65(9):1496-1503. PubMed ID: 29048508
[TBL] [Abstract][Full Text] [Related]
18. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
[TBL] [Abstract][Full Text] [Related]
20. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.
Moore DM; Hogg RS; Yip B; Wood E; Tyndall M; Braitstein P; Montaner JS
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):288-93. PubMed ID: 16249702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
